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Abstract
The ability of Interleukin-15 (IL-15) to activate many immune antitumor mechanisms renders the cytokine a good candidate
for the therapy of solid tumors, particularly renal cell carcinoma. Although IL-15 is being currently used in clinical trials, the
function of the cytokine on kidney’s components has not been extensively studied; we thus investigated the role of IL-15 on
normal and tumor renal epithelial cells. Herein, we analyzed the expression and the biological functions of IL-15 in normal
renal proximal tubuli (RPTEC) and in their neoplastic counterparts, the renal clear cell carcinomas (RCC). This study shows
that RPTEC express a functional heterotrimeric IL-15Rabcc complex whose stimulation with physiologic concentrations of
rhIL-15 is sufficient to inhibit epithelial mesenchymal transition (EMT) commitment preserving E-cadherin expression.
Indeed, IL-15 is not only a survival factor for epithelial cells, but it can also preserve the renal epithelial phenotype through
the cc-signaling pathway, demonstrating that the cytokine possess a wide range of action in epithelial homeostasis. In
contrast, in RCC in vitro and in vivo studies reveal a defect in the expression of cc-receptor and JAK3 associated kinase,
which strongly impacts IL-15 signaling. Indeed, in the absence of the cc/JAK3 couple we demonstrate the assembly of an
unprecedented functional high affinity IL-15Rab heterodimer, that in response to physiologic concentrations of IL-15,
triggers an unbalanced signal causing the down-regulation of the tumor suppressor gene E-cadherin, favoring RCC EMT
process. Remarkably, the rescue of IL-15/cc-dependent signaling (STAT5), by co-transfecting cc and JAK3 in RCC, inhibits
EMT reversion. In conclusion, these data highlight the central role of IL-15 and cc-receptor signaling in renal homeostasis
through the control of E-cadherin expression and preservation of epithelial phenotype both in RPTEC (up-regulation) and
RCC (down-regulation).
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Introduction
Interleukin-15 (IL-15) is a pleiotropic cytokine involved in
innate immunity as well as in functions outside the immune
system. IL-15 functional diversity is explained in part by its
complex mechanisms of action [1,2] involving not only soluble and
membrane forms of the cytokine but also different IL-15 receptors
(IL-15R) with specific affinities and signal transduction pathways
[3,4]. Indeed, IL-15 binds to the IL-15Ra private chain with high
affinity (Kd$10
211 M), which deliver a specific signaling in
response to IL-15 (NF-kB, Syk). IL-15 shares with IL-2 the IL-2Rb
(CD122) and IL-2Rc (CD132, cc) subunits, which form either a
functional receptor of high (IL-15Rabc,K d $10
211 M) or
intermediate affinity (IL-15Rbc, Kd=4 nM) for IL-15, allowing
signaling through a cascade that involves the JAK/STAT, MAPK
and PI3-K transduction pathways.
The common cc receptor chain is a key component of the four-
helix-bundle cytokines family, allowing through its association with
the Janus tyrosine kinase 3 (JAK3), the activation of STAT
molecules (Signal Transducers and Activators of Transcription)
[5]. JAK3 phosphorylates different downstream STATs, in
relationship to the type of the receptor complex involved. Thus,
IL-4 predominantly signals through STAT-6, whereas IL-2, IL-7,
IL-9 and IL-21 act through STAT-1 and STAT-3 and IL-15
mainly activates STAT-5 [6,7,8]. Both the cc and JAK3 are
essential for the function of all the cytokine receptors of this family
and are required for the development of the lymphoid cell system.
Indeed, genetic defects of cc or JAK3 results in a severe combined
immune deficiency (SCID) characterized by the lack of T, B and
NK cells in both mice and humans [9,10,11]. However, it must be
stated that in SCID patients, the corrective gene therapy for cc
can act as a contributor to genesis of cell lymphomas [9,11]. The
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detected for instance on certain tumoral epithelial cells [12,13,14]
where the amount of cc is involved in the mechanisms that govern
the cell growth. IL-2Rc is also found in normal epithelial cells
where it modulates signal transduction of different members of the
cc family even if its specific biological functions have not yet been
clearly defined [13,15,16].
The human epithelial cells of various tissues produce IL-15,
which acts not only on immune cells (e.g., IELs in the gut), but also
on epithelial cells, mainly via its anti-apoptotic action
[17,18,19,20]. Thus, it was shown that human and mouse renal
tubular epithelial cells (RPTEC) constitutively express the receptor
IL-15Rabc [15] and secrete the cytokine IL-15 [21], which plays
an important role in renal physiology as an autocrine survival
factor. Indeed, increased sensitivity of cells to apoptosis is observed
in the damaged kidney of IL-152/2, IL-15Ra2/2 knockout
mice or during acute renal injury induced by different protocols
that induce a decrease in IL-15 production by epithelial cells
[20,22]. IL-15 enhances intestinal barrier function by promoting
the formation of tight junctions between epithelial cells [23]. These
results suggest that the IL-15 survival factor may have other
functions, that remain to be explored in renal epithelial cells
[15,24,25,26].
Due to its immuno-stimulating activity in several preclinical
models, the use of IL-15 could be a useful cytokine for the
treatment of kidney cancers. Although IL-15 is currently being
tested in clinical trials for the treatment of kidney cancer
(NCT01021059 Protocol) [2], the functions of the cytokine on
normal epithelial cells as well as tumor cells remain poorly studied.
In order to better understand the functions of the cytokine, we
propose to study the IL-15/IL15R system on human kidney
epithelial cells of normal origin (RPTEC) and on cells of tumor
origin (RCC).
Our data show that both in vitro and in vivo primary normal renal
proximal tubular cells (RPTEC) express the IL-15Rabc receptor,
whereas expression of the cc chain and JAK3 is severely impaired
in renal clear cancer cells (RCC). The differential expression of cc
chain and JAK3 has a marked impact on renal homeostasis since
soluble IL-15 in RPTEC through the cc chain signaling pathway
preserves the expression of the tumor suppressor gene E-cadherin,
inhibiting their epithelial-mesenchymal transition (EMT) commit-
ment. By contrast, loss of the cc chain and JAK3 in primary RCC
leads to the formation of an unprecedented functional IL-15Rab
high affinity heterodimer, whose stimulation with soluble IL-15
causes the down-regulation of the E-cadherin expression favoring
the EMT process.
Materials and Methods
Antibodies, Cytokines, and Reagents
Antibodies (Abs) against IL-15 (L-20), IL-15Ra (sc-9172), IL-
2Rb (sc-1046), IL-2Rc (sc-670), JAK3 (sc-513), and vimentin (sc-
73260) were obtained from Santa Cruz Biotechnology (Dela-
ware, CA). Antibodies against phosphorylated ERK (4377),
phosphorylated IkB (4921), STAT5 (9358) phosphorylated
STAT5 (9356), and the Alexa fluor-conjugated rabbit monoclo-
nal antibody against phosphorylated STAT5 (3939) were
obtained from Cell Signaling (Beverly, MA). Antibodies against
IL-15Ra (AF247), E-cadherin (AF648) and PE-conjugated anti-
E-cadherin (FAB18381P) were obtained from R&D Systems
Europe Ltd (Abingdon, Oxon, U.K.), as well as neutralizing anti-
IL-2Rc (mAb2842) mAb. The FITC-conjugated anti-fibroblast
ASO2 was from Dianova GmbH (Hamburg, Germany) and the
pan-cytokeratin (CK) Ab from EXBIO (Prague, Czech Repub-
lic). Rhodamine-conjugated phalloidin for F-actin detection and
zonula occludens-1 (ZO-1) were obtained from Invitrogen
(Cergy Pontoise, France). Antibody against JAK3 (07-1488)
was from Millipore (Saint-Quentin-en-Yvelines, France) and
anti-IL-2Rb (AB364) was from Assay Biotech (Interchim
BioScience Innovations, France). The anti-b-actin mAb
(A1978) was from Sigma-Aldrich (St. Louis, MO, USA).
Recombinant human non-glycosylated IL-15 (rhIL-15) and
neutralizing anti-IL-2Rb Mikb1 mAb were obtained from
ImmunoTools (Friesoythe, Germany) and Horseradish peroxi-
dase (HRP)-conjugated and fluorescent-conjugated secondary
Abs were from Jackson ImmunoResearch. JAK3 inhibitor (CP-
690, 550) and STAT5 inhibitor (573108) were purchased from
Calbiochem (SD, CA). Anti-IL-15Ra M161 mAb was provided
by Amgen (Thousand Oaks, CA).
Primary cells and cell lines
Primary human normal Renal Proximal Tubular Epithelial Cell
(RPTEC) derived from a non-cancerous kidney (Lonza, Verviers,
Belgium) and expanded in vitro following manufacturer’s instruc-
tions. REGM culture medium of RPTEC was daily changed to
maintain epithelial characteristics. Primary tumor cells were
obtained by enzymatic digestion of fragments of clear cell renal
carcinomas (RCC) as described previously [27]. Subsequently, the
digested cellular suspensions were seeded onto plastic Petri dishes
using RPMI 1640 supplemented with 10% fetal calf serum, 1%
MEM sodium pyruvate, 1% penicillin/streptomycin (Life Tech-
nologies). In these culture conditions, only a fraction of cells
adheres to the plastic surface and proliferates, generating RCC
primary cultures and subsequently cell lines (RCC5, RCC7,
RCC8).
The human kidney carcinoma ACHN (ATCC, CRL-1611),
MCF-7 (human breast cancer cells) and U937 (human monocytic
leukemia cells) cell lines were cultivated as described above. The
erythroleukemia cell line TF1b was maintained in RPMI 1640
medium supplemented with 5 ng/ml GM-CSF and 250 mg/ml
geneticin G418. Peripheral Blood Lymphocytes (PBL) were
prepared as previously described [28]. Human samples were
collected and handled in the full respect of the declaration of
Helsinki.
Reverse-transcription (RT)-PCR analysis. Reverse-
transcription (RT)-PCR analysis was performed as previously
described [29]. Specific RT-PCR primers are detailed below.
IL-15Ra F5 9-GGCGACGCGGGGCATCAC; R 59-TGCC-
TGTGGCCCTGTGGATA; IL-2Rb F5 9-GAATTCCCTGGA-
GAGATGGCCACGGTCCCA; R 59-GAATTCGAGGTTTG
GAAATGGATGGACCAAGT; cc chain F 59-CCAGGACC-
CACGGGAACCCA; R 59-GG TGGGAATTCGGGGCATCG;
JAK3 F 59-CGTTCATGCAGCCTCTTGTTC; R 59-GCGCA
CCGTCCTCCGAATAC; b-actin F 59-GTGGGGCGCCCC-
AGGCACCA; R 59-CTCCTTA ATGTCACGCACGATTTC.
IL-15 binding assays
Human rIL-15 was radiolabeled with iodine (specific radioac-
tivity approximately 2000 cpm/fmol) using a chloramine-T
method and binding experiments were performed as described
previously [30]. Nonspecific binding was determined in the
presence of 100-fold excess of unlabeled cytokine. For the IL-15
binding experiments, RCC7 cells were incubated with increasing
concentrations of labeled rIL-15. Regression analysis of the
binding data was accomplished using a one-site equilibrium
binding equation (Grafit, Erithacus Software, Staines, UK), and
data were plotted in the Scatchard coordinate system. For
inhibition of IL-15 binding experiments, RCC7 cells were
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rIL-15, and fixed concentrations of neutralizing antibodies against
IL-2Rb (Mikb1, 10 mg/ml) or IL-2Rc (mAB2842, 1 mg/ml)
chains. Regression analysis of data was accomplished using a 4-
parameter logistic equation (Grafit, Erithacus Software).
Plasmids and transient transfection
pCMV6 vector encoding full-length cDNA Myc-DDK-tagged
ORF of human interleukin 2 receptor gamma (IL2Rc) was
purchased from Origene Technologies Inc (Rockville, MD, USA)
and full length human JAK3 cDNA subcloned between the
EcoRI-XhoI restriction sites of the pcDNA3.1 eukaryotic expres-
sion vector was a kind gift from Dr. Franck Gesbert (UMR1004,
Inserm, France). Plasmids were transformed into Top 10
competent bacteria cells according to the manufacturer’s protocol
(Invitrogen, Carlsbad, CA), extracted using a Maxiprep kit
(Qiagen, Valencia, CA), and amplified by culture in Luria-
Bertani-ampicillin broth. cDNAs were transiently transfected into
cells according to manufacturer’s instructions. Briefly, cells were
plated into six-well plates (0.25610
6 cells/well) and cultured
overnight in complete medium. The transient mixture, which
contained 1.0 mg of plasmid DNA and 6 ml of Fugene 6
transfection reagent (Roche Diagnostics, Indianapolis, IN) in
100 ml of serum-free DMEM medium (Invitrogen), was mixed for
20 min at room temperature and then added to each well with
complete medium for 48 h. The empty pcDNA3.1 vector was
transfected as control.
Flow Cytometry Analyses
For all assays described below, we acquired fluorescence data
for 10,000 cells on a FACScalibur flow cytometer (BD Biosciences)
and the data was analyzed using CellQuest software (BD
Biosciences). Three replicates were used for each condition and
the experiment was repeated at least three times.
Expression of Cellular Antigens. Expression of cell surface
(E-cadherin) and intracellular (Vimentin, Pan-CK) antigens was
analyzed by flow cytometry as previously described [29,31,32].
Briefly, suspensions of enzymatically detached cells were
permeabilized or not with BD Cytofix/Cytoperm reagent (BD
Pharmingen, Le Pont De Claix, France), and 10
5 cells were
suspended in RPMI medium supplemented with 1% FCS and
stained with conjugated antibodies directed against the above-
mentioned cell markers. Subsequently, cells were fixed by
incubation with 1% paraformaldehyde in phosphate-buffered
saline (PBS) for 20 minutes at room temperature and analyzed by
flow cytometry.
STAT5 Activation. We investigated STAT5 activation in
RCCWT (RCC wild type) and IL-2Rc and/or JAK3-transfected
RCC by treating cells with 10 pg/mL of rhIL-15 during
40 minutes. Treated and untreated cells were detached by
trypsin, washed, and fixed by incubation with 1%
paraformaldehyde in PBS for 20 minutes at room temperature.
The cells were permeabilized by resuspension, with vortexing, in
ice-cold methanol and incubated at 4uC for 10 minutes. The cells
were washed in 1% BSA in PBS and incubated with an Alexa
Fluor 488–conjugated mouse monoclonal antibody against
phosphorylated STAT5 for 60 minutes at 4uC.
Immunoprecipitation and immunoblot Analyses
All immunoblotting (WB) were performed as previously
described [29]. For immunoprecipitation, PBS-washed cell pellet
was lysed in 1 ml 1% NP-40 and 0.1% SDS, 50 mM sodium
phosphate buffer pH 7.8, 150 mM NaCl, 1 mM sodium ortho-
vanadate, 1 mM EDTA, 1 mM EGTA, 1 mM AEBSF, aprotinin,
leupeptin and pepstatin (5 mg/ml each). After 15 min shaking at
4uC, the suspension was centrifuged (30 min at 14,000 rpm, 4uC).
The supernatant was added to 20 ml of Sepharose-conjugated-
M161 (anti-IL-15Ra,2mg/ml). After 4 h agitation at 4uC, the
immune complexes were washed 5 times with 1 ml of lysis buffer
and applied on 10% PAGE-SDS. Blots were processed as
previously described [29].
Immunocytochemistry
Cells were dispensed into eight-well compartments of Lab-Tek
tissue culture chamber slides (1610
5 cells per well; Nunc,
Naperville, Ill.) and at confluence, treated or not with 10 pg/ml
of rhIL-15 for 5 days. For membrane staining, cells were fixed with
cold methanol:acetone (1:1) at 220uC for 10 min, washed then
blocked with PBS 3% BSA for 60 min. Cells were incubated with
anti-human E-cadherin or FITC-conjugated anti-ASO2 antibod-
ies overnight at 4uC. Subsequently, cells were washed, incubated
for 30 min with an AlexaFluor488-conjugated rabbit anti-goat
antibody. For intracellular staining, the cells were fixed with 4%
(wt/vol) paraformaldehyde in PBS and permeabilized by incuba-
tion for 1 minute with 0.5% Triton X-100 in PBS. The cells were
incubated with blocking solution (3% BSA in PBS) and incubated
overnight at 4uC with the various antibodies. The cells were then
washed and incubated with Alexa Fluor 488–conjugated rabbit
anti-mouse or anti-goat IgG diluted in blocking solution and
incubated for 30 minutes. F-actin organization was revealed
staining the cells with 0.2 mg/mL of rhodamine-conjugated
phalloidin for 20 minutes. The cells were washed with PBS,
mounted in 4,6-diamidino-2-phenylindole (DAPI, Invitrogen,
Cergy Pontoise, France), and visualized by fluorescence micros-
copy (Leica, Germany).
Immunohistochemistry on Paraffin-Embedded renal
tumor and normal samples
Biopsies from 3 normal and 10 tumor sections from nephrec-
tomized kidneys with renal cell carcinoma were sectioned at 4 mm
onto Superfrost plus slides. Deparaffinized slides were rehydrated
in graded alcohols, and subjected to heat-induced epitope retrieval
by immersing them in 0.01 mol/L citrate buffer (pH 6.0). Sections
were incubated overnight at 4uC with anti-IL-2Rb (AB364), anti-
IL-2Rc (sc-670) or anti-JAK3 (07-1488) Abs, PBS-rinsed and
incubated with HRP-secondary Ab for 45 min. Analysis was
performed by standard methods using diaminobenzidine after
counterstaining the sections with hematoxylin. The negative
control was subjected to all treatments omitting primary antibody.
Slides were scanned using an Aperio scanner (Vista, CA) and
staining was quantified using a morphometric TRIBVN software
(Montrouge, France).
Results
IL-15R expression in RPTEC and RCC primary cultures
In order to shed light on the function of IL-15 in the renal
human model, we investigated the expression of IL-15 receptor
subunits (IL-15Rabc) on primary cultures of normal Renal
Proximal Tubular Epithelial Cell (RPTEC) and clear cell renal
carcinomas (RCC).
RT-PCR analysis (Figure 1A, upper panel) shows that RPTEC,
in agreement with the positive PBL control, express different
transcripts for the IL-15Ra chain (432 and 531 bp), the transcript
for the IL-15Rb (542 bp) and the transcript for the cc chain
(480 bp). In contrast, only the IL-15Ra and b chains, but not the
cc chain, were detected either on RCC (RCC5 and RCC7) or
ACHN cell line. Since JAK3 kinase specifically interacts with its
IL-15 Role in Human Kidney Physiology and Cancer
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interdependent [33], we further analyzed, by RT-PCR, JAK3
expression in normal and tumor renal cells (Figure 1A, lower
panel). JAK3 kinase was detected in the positive haematopoietic
control cell line TF1b and RPTEC, while a weak messenger
amount or absent (RCC8) was detected in RCC analysed. No
JAK3 messenger was detected in the MCF-7 control cell [34].
To confirm the differential expression of the receptor subunits
and the JAK3 kinase at the protein level, immunoblotting was
performed on both normal and tumoral cells. The analysis
confirmed that RPTEC, RCC and TF1b cells express two major
bands of 46 and 56 kDa specific for the IL-15Ra (Figure 1B,
upper panel) and a 75 kDa band for the IL-15Rb chain (Figure 1B,
middle panel). The absence of the cc chain in RCC was confirmed
since the 64 kDa band is detected exclusively in positive control
cell lines (TF1b and IFN-c treated U937) and RPTEC (Figure 1B,
middle panel). JAK3 molecule (116 kDa) was detected in TF1b
and RPTEC cells, whereas immunoblotting did not detect the
kinase in RCC, as well as in MCF-7 and IFN-c treated U937
control cell lines as previously reported [34,35] (Figure 1B, lower
panel). In all above-mentioned experiments, we also studied renal
ATCC-CRL-1611 cell line (ACHN) that display IL-15R and
JAK3 expression homologous to those observed in RCC primary
samples.
Loss of cc chain in renal clear cell carcinoma tissues
samples
In order to confirm our in vitro data, IL-2Rb chain, cc chain and
JAK3 immunohistochemical stainings were performed on normal
and tumor sections of nephrectomized kidneys with renal cell
carcinoma. Hematoxylin staining of paraffin embedded human
kidney sections revealed under light microscopy the presence of
glomeruli (Gl) and several distal (Dt) and proximal (Pt) tubules in
the normal tissue samples (Figure 2). By contrast, these kidney
structures are no longer present in the renal carcinoma section,
showing tumor cells with clear cell morphology, characterized by
optically clear cytoplasm and sharply outlined cell membrane.
Immunohistochemical staining on two different normal renal
specimens reveals that the IL-2Rb chain, cc chain and a strong
JAK3 expression are detected on proximal and distal tubular cells.
By contrast, analysis of different tumor samples revealed the
absence of cc chain staining (P,0.01) with a very faint JAK3
protein expression (P,0.01) while, no significant differences
(P.0.05) in the expression of the IL-2Rb chain were observed
between normal and tumoral tissues therefore confirming the
results obtained in vitro in primary cultures of normal and cancer
cells.
Soluble IL-15 triggers a differential cell signal in RCC and
RPTEC
To our knowledge, the IL-15Rab heterodimer was only
described in IL-2Rc2/2 knockout mice, that exhibits an efficient
binding and endocytosis of radiolabeled IL-15 [36]. However, the
authors did not investigate whether the IL-15Rab heterodimer
exists as a preformed complex or is formed following IL-15
binding thereby generating a functional heterodimer.
To evaluate IL-15 binding on cc-negative RCC, we first
analyzed radiolabeled recombinant human IL-15 (rhIL-15)
binding to RCC7 cells by Scatchard’s plot analysis (Figure 3A).
The data reveals the presence of a single class of high affinity
receptors (Kd=375 pM, 413 IL-15 binding sites per cell). Specific
IL-15 binding was completely abrogated by the anti-IL-2Rb mAb
Mikb1 (Figure 3A, inset), while neutralizing anti-IL-2Rc mAb had
no effect on specific IL-15 binding, suggesting that the binding
indeed reflected the presence of an IL-15Ra/IL-2Rb complex.
To confirm the presence of an IL-15Ra/IL-2Rb complex
heterodimer, the potential interactions between the IL-15Ra and
IL-2Rb chains in RCC were investigated performing co-
immunoprecipitation experiments on RCC7 cell lysates by
immunoadsorption to Sepharose-conjugated anti-IL-15Ra
(M161) (Figure 3B). Anti-IL-2Rb immunoblotting reveals the
presence of a specific 75 kDa protein (upper panel) while anti-IL-
15Ra blot, performed on the same membrane, shows the
expression of specific bands of 56 and 46 kDa (lower panel)
indicating that IL-2Rb and IL-15Ra receptor subunits are
constitutively associated, forming an IL-15Rab heterodimer in
the absence of the cytokine.
In order to determine whether the IL-15Rab complex
expressed on RCC is functional, we investigated signal transduc-
tion activation in normal and tumor renal cells treated with
physiologic (10 pg/mL) and supra-physiologic (10 ng/mL) con-
centrations of rhIL-15 (Figure 3C). Stimulation with rhIL-15 (10–
40 min) induced in RCC7 the phosphorylation of the MAPK
ERK1/2 at both concentrations, while no STAT5 phosphoryla-
tion was observed even in the presence of 10 ng/mL rhIL-15
(Figure 3B, upper panel). In contrast, in RPTEC expressing the
heterotrimeric receptor complex, the activation of MAPK ERK1/
2 and STAT5 was induced in response to 10 pg/mL and 10 ng/
mL of rhIL-15. Moreover, there is a rapid phosphorylation of
IkBa, a key event in the activation of the transcription factor NF-
kB, in RPTEC and RCC7 in response to physiologic rhIL-15
concentration (Figure 3B, lower panel), indicating that the IL-
15Rab complex binds IL-15 at high affinity and is functional.
Soluble IL-15 controls E-cadherin expression on renal
epithelial cells
E-cadherin is responsible for maintaining interactions of
epithelial cells and is frequently down-regulated during tumor
progression [37]. Thus, we investigated the effects of rhIL-15 on
E-cadherin expression on both RCC7 and RPTEC by immuno-
fluorescence analysis (Figure 4A) and immunoblotting (Figure 4B).
To evaluate the effect of rhIL-15 on normal RPTEC, we used a
cell model where the deprivation of corticosteroids, that are
powerful inducers of E-cadherin [38], together with absence of
daily medium renewal leads within five days to the decrease of E-
cadherin expression, without affecting cell viability (97%, data not
shown). Immunofluorescence analysis (Figure 4A) shows that
normal epithelial cells RPTEC in the first passages (p2) display an
epithelial-like morphology characterized by a high level of
membrane E-cadherin expression (basal d0) in contrast to five
days old RPTEC (basal d5) that exhibit low E-cadherin expression
in absence of daily medium renewal. Addition of 10 pg/mL of
rhIL-15 during five days preserves the initial E-cadherin level and
Figure 1. Normal and tumoral renal epithelial cells express different IL-15R subtypes. Analysis of IL-15R and JAK3 expression was
performed by RT-PCR (A) and immunoblotting (B) on primary normal (RPTEC) and tumoral (RCC5, RCC7, RCC8) epithelial cells and the ACHN cell line.
Data show that RPTEC express the three chains of the IL-15R (abc) and JAK3 whereas cc and JAK3 proteins were not detected in RCC. Specific primers
or Abs against IL-15Ra (AF247), IL-2Rb (sc-1046), IL-2Rc (sc-670) and JAK3 (sc-513) were used. PBL, TF1b, MCF7 and IFNc-activated U937 cells were
used as controls. Housekeeping b-actin was used as loading control.
doi:10.1371/journal.pone.0031624.g001
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e31624Figure 2. Immunohistochemical staining for IL-2Rb, IL-2Rc and JAK3 in normal and neoplastic kidney specimens. Hematoxylin staining
of biopsies from 2 normal samples reveals the presence of the normal kidney structures (glomerulus (Gl), distal (Dt) and proximal (Pt) tubules), while
analysis of two different cancer specimens shows that the normal tissue architecture is totally lost and are replaced by tumor cells with clear cell
morphology, characterized by optically clear cytoplasm and sharply outlined cell membrane. Whereas no difference on IL-2Rb is observed between
normal and tumoral tissue samples, the IL-2Rc staining, localized to both proximal and distal tubuli in normal tissue samples, is not found in the
tumor samples. A strong JAK3 staining is localized to both proximal and distal tubular cells of normal tissues, while a very faint JAK3 protein
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RCC7 at day 0 and day 5 display a weak E-cadherin expression,
which disappears after 5 days of rhIL-15 treatment (Figure 4A).
Immunoblotting analysis (Figure 4B) clearly shows the opposite
effects of rhIL-15 on the expression of the mature 120 kDa E-
cadherin form on RPTEC versus RCC (day 5).
In the light of these data, we asked whether the absence of the
cc chain could be involved in the differential modulation of E-
cadherin expression by rhIL-15 in RPTEC versus RCC. For this
purpose, we used neutralizing anti-cc chain antibody as well as
specific inhibitors against JAK3 and STAT5, two molecules
involved in the IL-15-induced cc chain signaling. Flow cytometry
analysis (Figure 5) showed that the maintenance of E-cadherin by
rhIL-15 in RPTEC is counteracted by the neutralizing anti-cc
chain antibody (left panel), JAK3 (middle panel) and STAT5 (right
panel) specific inhibitors while the different treatments did not
interfere with the E-cadherin basal expression on RPTEC. These
data strongly support the direct involvement of the IL-2Rc chain
signaling in E-cadherin modulation on renal human epithelial
cells. In contrast, anti-cc chain antibody and specific JAK3 and
STAT5 inhibitors do not interfere with rhIL-15 induced E-
cadherin down-regulation in RCC7. All the above data underline
that IL-15 appears to play a major role in the renal homeostasis,
regulating E-cadherin expression.
Since rhIL-15 down-regulates E-cadherin expression on RCC
lacking IL-2Rc and JAK3, we asked whether after co-transfection
of both molecules it was possible to reestablish IL-15 downstream
signaling and subsequently induced E-cadherin expression as
observed on RPTEC. RCC7 were transiently transfected for
48 hours with vectors containing IL-2Rc and/or JAK3 Human
cDNA and expression of both molecules was analyzed by
immunoblotting (Figure 6A). As expected, the data confirmed
that IL-2Rc chain, JAK3 or both are well expressed after 48 hours
in transfected RCC. Flow cytometry (Figure 6B) showed that
40 min rhIL-15 treatment did not induce STAT5 phosphorylation
in cc- or JAK3-transfected RCC while rhIL-15 activated STAT5
phosphorylation in co-transfected cells (cc/JAK3-RCC7), suggest-
ing that expression of both molecules is necessary to reestablish the
STAT5 signal transduction pathway in RCC. In the light of these
results, it was interesting to determine whether the reestablishment
of IL-2Rc chain-dependent signal transduction pathway in RCC
could interfere with the rhIL-15-induced E-cadherin down-
regulation. The introduction of either IL-2Rc chain, JAK3 or
both molecules did not modify E-cadherin expression on untreated
rhIL-15 cells, while the E-cadherin down regulation observed after
48 hours of rhIL-15 treatment was counterbalanced only in co-
transfected cells (cc/JAK3-RCC7).
E-cadherin modulation by soluble IL-15 controls EMT on
renal epithelial cells
Since down-regulation of E-cadherin, causing the loss of cell-cell
adhesions is a key initial step in the process of tubular epithelial-
myofibroblast transdifferentiation [39,40,41], we asked whether
IL-15, which controls E-cadherin expression, could influence this
process. Thus, we examined by immunofluorescence the mor-
phology and the cytoskeleton reorganization analyzing several
epithelial and mesenchymal molecular markers both on normal
RPTEC, deprived of corticosteroids and of daily medium renewal,
and on RCC. Deprivation of corticosteroids, together with
absence of daily medium change induceed within five days in
RPTEC, not only the decrease of E-cadherin expression
(Figure 4A), but also an EMT-like phenotype (Figure 7A),
characterized by the loss of epithelial markers (cytokeratins (CK)
and zonula occludens-1 (ZO-1)) and the acquisition of a fibroblast-
like morphology. The mesenchymal phenotype is characterized by
the strong expression of the surface fibroblast marker ASO2 [42]
and by a cytoskeletal reorganization represented by the formation
of large alpha smooth muscle actin (a-SMA) stress fibers and a
diffuse vimentin network. Remarkably, five days IL-15 treatment
(10 pg/mL) prevents RPTEC from EMT commitment since these
cells maintain their initial epithelial-like morphology (basal d0),
characterized by the expression of the epithelial markers CK and
ZO-1 and the absence of detectable a-SMA and vimentin
networks. By contrast, five days of rhIL-15 treatment (10 pg/
mL) induced the opposite effects on RCC, causing not only the
decrease of E-cadherin on RCC (Figure 4A), but also favoring the
acquisition of a mesenchymal-like phenotype, as shown by the loss
of epithelial markers (cytokeratins and ZO-1) and by the
enhancement of vimentin and a-SMA stress fibers networks
(Figure 7A).
In the light of these results, it was interesting to find out whether
the reestablishment of the IL-2Rc chain-dependent signal
transduction pathway in RCC could interfere with the rhIL-15-
induced epithelial-myofibroblast transdifferentiation process. Flow
cytometry (Figure 7B) shows that the introduction of IL-2Rc chain
or JAK3 does not modify cytokeratins and vimentin expressions on
untreated and rhIL-15-treated RCC (data not shown). In
agreement with the data observed on E-cadherin expression
(Figure 6C), only the IL-2Rc/JAK3 co-transfection in RCC
inhibits the cytokeratins down-regulation and vimentin upregula-
tion observed after 48 hours of rhIL-15 treatment. It should be
emphasized that the reestablishment of the IL-2Rc chain-
dependent signal transduction pathway in RCC, inhibits the
rhIL-15-induced EMT process preserving the E-cadherin expres-
sion.
Discussion
The clear cell renal cell carcinoma (RCC) is one of the most
resistant solid tumors to chemo-and radiotherapy. The modest
results obtained in the treatment with IL-2 and IFN-a require the
development of new immuno-therapies. In this context, IL-15,
which is currently used in clinical trials for the treatment of kidney
cancer (NCT01021059 Protocol) [2] could be an useful alternative
based on its immuno-activation activities [43]. However, it is
important to be aware of the potential side effects of IL-15 on
renal epithelial cells, especially tumor cells since until now the IL-
15 action in renal physio-pathology is still not completely
understood [20,44,45]. In this context, studies in IL-15 (IL-
152/2) and IL-15Ra (IL-15Ra2/2) deficient mice indicate that
intrarenal IL-15 is an autocrine anti-apoptotic factor for renal
tubular epithelial cells [20,22], highlighting the central role of IL-
15 and IL15Ra chain in renal homeostasis as survival factors.
However, the role of the other IL-15R subunits and namely of IL-
2Rc (CD132) in the kidney is yet to be determined. Moreover, IL-
15 has been found to participate in the development of solid
tumors [43] notably, in renal carcinoma where, stimulation of the
membrane-bound IL-15 by soluble IL-15Ra chain favors
expression is detected in tumor samples. Two representative samples of a total of ten are shown for each staining. Negative control was subjected to
all treatments omitting primary antibody. Scale bars, 50 mm. Staining was quantified using a morphometric TRIBVN software (Montrouge, France) and
results are presented as histograms.
doi:10.1371/journal.pone.0031624.g002
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PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e31624Figure 3. Soluble IL-15 triggers a differential cell signal in RCC and RPTEC. A) Scatchard’s plot analysis: Effects of anti-IL-15Rb and
cc mAbs on IL-15 binding to RCC. For the IL-15 binding experiments, RCC7 cells were incubated with increasing concentrations of radioiodinated
rIL-15 in presence or not of the following neutralizing mAbs: anti-IL-2Rb and IL-2Rc. The nonspecific cell binding was determined in the presence of
radioiodinated rhIL-15 and a 100-fold excess of unlabeled rhIL-15. Cell-bound (B) and unbound (free, F) fractions were measured, and the specific
bound fraction was calculated by subtracting the nonspecific binding from the cell-bound fraction. On the ordinate is plotted the ratio of the specific
bound fraction (expressed in sites per cell) over the total concentration (bound plus free) of radioiodinated rIL-15 (expressed in pM). On the abscissa
bound fraction (expressed in sites per cell). The high affinity specific IL-15 binding (Kd=375 pM, 413 IL-15 binding sites per cell), which was
completely abrogated by neutralizing antibody against the IL-2Rb (inset) but not the cc chain, suggested the presence on RCC of an IL-15Ra/IL-2Rb
complex. B) Detection of IL-15Rab complex by immunoprecipitation (IP) with anti-IL-15Ra (M161) or mouse IgG protein G-Sepharose-conjugate on
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31624epithelial to mesenchymal transition [29]. Therefore, IL-15
application in tumor therapy should always be approached with
caution and should be preceded by a careful examination of its
effects in the appropriate tumor cells in vitro [43]. Taken together,
these observations led us to reassess the role of IL-15 in primary
cultures of human tubular epithelial renal cells of normal (RPTEC)
and tumoral (RCC) origin.
As shown previously, our data show that primary RPTEC
express a functional heterotrimeric IL-15Rabc complex whose
stimulation with physiological concentrations of rhIL-15 (10 pg/
total lysate (TL) of RCC7. Immunoprecipitated complexes were blotted either with anti-IL-2Rb (sc-1046) and anti-IL-15Ra (sc-9172). C) Stimulation for
10 and 40 min with physiologic (10 pg/mL) and supra-physiologic (10 ng/mL) concentrations of rhIL-15 induces the phosphorylation of MAPK ERK1/2
and IkBa in RPTEC and RCC7, whereas STAT5 activation was only observed in RPTEC. Histograms represent densitometry comparison of each factor
normalized to b-actin in 3 different RCC (RCC5, RCC7, RCC8) and 3 RPTEC batches. * P,0.05 versus control, Mann-Whitney test. One experiment
representative of a total of three is shown.
doi:10.1371/journal.pone.0031624.g003
Figure 4. Soluble IL-15, at physiologic concentration, differently controls E-cadherin expression in RCC and RPTEC.
Immunofluorescence analysis (A) and immunoblot (B) show that 5 days rhIL-15 treatment (10 pg/mL) preserves membrane E-cadherin expression
on primary normal epithelial cells RPTEC, whereas it induces its down-regulation on RCC7. The medium culture of RPTEC was not changed in order to
induce the decrease of E-cadherin expression. Treatment with rhIL-15 was renewed at day 3. Histograms represent densitometry comparison of E-
cadherin immunoblots normalized to b-actin in 3 different RCC (RCC5, RCC7, RCC8) cells and 3 RPTEC batches. * P,0.05.
doi:10.1371/journal.pone.0031624.g004
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chain (IkBa), IL-2Rb chain (MAPK-ERK1/2) [46] and IL-2Rc
chain (STAT5) [6,8]. In a model where the deprivation of
corticosteroids, together with absence of daily medium change,
induces within five days in RPTEC an epithelial-mesenchymal
transition (EMT), we show that addition of physiologic concen-
trations of rhIL-15 is sufficient to inhibit EMT commitment
preserving E-cadherin expression, a main component of the
adherent junctions and a master programmer of the EMT process
[39,40,41]. Furthermore, the up-regulation of E-cadherin expres-
sion by rhIL-15 in RPTEC is dependent on the cc chain-signaling
pathway as shown by the use of neutralizing anti-cc mAb and
specific inhibitors for JAK3 and STAT5. Our data show that IL-
15 is not only a survival factor for epithelial cells but also can
preserve through the cc-signaling pathway, renal epithelial
phenotype demonstrating that the cytokine possess a wide range
of actions in epithelial homeostasis, as already shown for other
tissues [25].
The major feature distinguishing primary normal epithelial
renal tubular cells from those derived from clear cells renal
adenocarcinomas is represented by the differential expression of
the cc chain and of its cognate kinase JAK3 both in vitro and in
tissue specimens derived from normal kidneys and renal clear cells
adenocarcinomas. Indeed, primary RCC are characterized by the
loss of the cc chain both at the transcriptional and protein levels,
by a weak expression of JAK3 transcripts and by the lack of the
functional 116 Kda JAK3 [47]. Immunohistochemical analysis on
tissue specimens from renal clear cell adenocarcinomas highlights
in comparison with normal counterparts the absence of cc chain
expression and a strong decrease of JAK3 expression (270%).
Scatchard’s plot analysis on RCC reveals the presence at the cell
surface of a single class of high affinity receptors (Kd=375 pM,
413 IL-15 binding sites per cell). The specific IL-15 binding, which
was completely abrogated by neutralizing antibody against the IL-
2Rb but not the cc chain, suggested the presence on RCC of an
IL-15Ra/IL-2Rb complex, whose existence was confirmed
performing co-immunoprecipitation experiments. Previous data
on cc
2/2 knockout mice reported the existence of IL-15Rab
heterodimers able to induce IL-15 endocytosis, but without
demonstrating its capacity to induce signal transduction [36].
Indeed, stimulation of RCC with physiological concentrations
of rhIL-15 triggers the signal dependent on the IL-15Ra (IkBa),
the IL-2Rb chain (MAPK-ERK1/2) [46], but not on the cc chain
(STAT5) [6,8]. The phosphorylation of ERK1/2 is a key-signaling
event for the induction of the EMT process in response to several
different inducers [48,49,50,51,52,53]. This IL-15 signal in RCC
induces the loss of E-cadherin expression [54], and favors the loss
of the epithelial phenotype leading to the acquisition of a
migratory one [39,40,41]. This hypothesis is supported by the
results of transfection experiments showing that transient co-
expression of cc chain and JAK3, necessary to reestablish the cc
chain-dependent IL-15 signaling (phosphorylation of STAT5),
counterbalances the IL-15 effects on RCC, inhibiting EMT
process. Indeed, rhIL-15 preserved on cc/JAK3 co-transfected
RCC the expression of epithelial markers (E-cadherin and
cytokeratins) inhibiting the up-regulation of mesenchymal markers
as vimentin.
Transfection of JAK3 or the cc chain alone in RCC is not
sufficient to reestablish the cc chain-dependent IL-15 signaling
(phosphorylation of STAT5), which is restored only after co-
transfection of both molecules. These data demonstrate the
existence in RCC of a double defect involving both the cc chain
and the 116 kDa JAK3 isoform. The loss of expression of the IL-
2Rc/JAK3 couple in RCC is not induced by mutations [55], as
observed in syndromes of severe combined immunodeficiency
(SCID) [9] but probably related to different mechanisms of post
transcriptional control targeting IL-2Rc could involve its mRNA
stability [56], while the loss of JAK3 expression in vitro and its weak
expression in vivo may depend on the level of expression and
activation of the tyrosine phosphatase SHP1, which negatively
regulates JAK3 [57]. Alternatively, the residual expression of
JAK3 in samples of renal cancer could be explained by the
presence of splice variants of JAK3 lacking the kinase activity
essentially detected in various human epithelial cancers cells [47].
These data highlight the central role of IL-15 cc-signaling in
renal epithelial homeostasis and strengthen the fact that the loss of
Figure 5. Up-regulation of E-cadherin expression by rhIL-15 on RPTEC is dependent of the bc-dependent signaling pathway. The cc
neutralization, as well as JAK3 or STAT5 inhibition, hamper the maintenance of E-cadherin surface expression induced by rhIL-15 on RPTEC without
interfering on the E-cadherin down-regulation on rhIL-15-treated RCC7. Cells were pretreated with 1 mg/ml of neutralizing anti-IL2Rc antibody
mAb2842, 0.25 mM of JAK3 inhibitor (CP-690, 550, Calbiochem) or 100 mM of STAT5 inhibitor (STAT5 Inh., 573108, Calbiochem) for 1 h before adding
the recombinant cytokine (10 pg/mL) for 5 days. Treatment with rhIL-15 and STAT5 inhibitor was renewed at day 3. White histograms refer to
isotype-matched control. Mean fluorescence intensity values for each marker are shown in each histogram. The data are representative of 3 separate
experiments performed using different RCC (RCC5, RCC8) and RPTEC batches.
doi:10.1371/journal.pone.0031624.g005
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PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e31624Figure 6. Reestablishment of IL-2Rc chain-dependent signal transduction pathway in RCC interferes with the rhIL-15-induced E-
cadherin down-regulation. RCC7 were transiently transfected for 48 hours with vectors containing IL-2Rc and/or JAK3 Human cDNA. A) Transient
expression of IL-2Rc and JAK3 was analyzed by immunoblotting in each transfected RCC. Immunoblotting for b-actin was used as a control for equal
protein loading and transfer. B) Flow cytometry shows that 40 min rhIL-15 treatment did not induce STAT5 phosphorylation in IL-2Rc- or JAK3-
transfected RCC while rhIL-15 treatment induced STAT5 phosphorylation in co-transfected cells. C) After 48 h, transfected RCC were treated for an
additional 48 h with 10 pg/mL of rhIL-15 before evaluating E-cadherin expression by flow cytometry. The introduction of either IL-2Rc chain, JAK3 or
both molecules do not modify E-cadherin expression on untreated rhIL-15 cells, while the E-cadherin down-regulation observed after 48 hours of
rhIL-15 treatment was counterbalanced only in co-transfected cells. Mean fluorescence intensity values for each marker are shown in each histogram.
One experiment representative of a total of three is shown.
doi:10.1371/journal.pone.0031624.g006
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PLoS ONE | www.plosone.org 11 February 2012 | Volume 7 | Issue 2 | e31624the cc chain in renal clear cell adenocarcinomas could represent a
mechanism that through E-cadherin down-regulation not only
favors EMT but may also affect trafficking, survival and functions
of different subsets of CD8+ cells. In this respect, the potential role
of the CD8+/CD103+ tumor infiltrating T lymphocytes (T-TILs),
which exert powerful T cytotoxicity against tumor cells, through
CD103/E-cadherin interactions is of particular interest [58,59].
In conclusion, these data underline a novel role of IL-15,
through the cc-signaling pathway, in the preservation or not of
renal epithelial homeostasis according to the positive (RPTEC) or
negative (RCC) regulation of E-cadherin expression. However, on
the basis of these results it must be stated that at present there is no
evidence that absence of cc/JAK3 is involved in the initiation of
renal clear cell carcinoma.
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Figure 7. E-cadherin modulation by soluble IL-15 controls epithelial-mesenchymal transition on renal epithelial cells. A)
Immunofluorescence of cell–cell adhesion molecules show that IL-15 favors epithelial-mesenchymal transition (EMT) on RCC7, whereas it preserves
the EMT commitment of RPTEC. The medium culture of RPTEC was not changed in order to induce the EMT process. Cells stimulated or not with
10 pg/ml of rhIL-15 for 5 days, were fixed and stained using standard immunofluorescence procedures with Abs against epithelial (cytokeratins and
ZO-1) and mesenchymal markers (F-actin, ASO2 and vimentin). Similar results were obtained using different RCC (RCC5, RCC8) and RPTEC batches. B)
After 48 h, transfected RCC were treated for an additional 48 h with 10 pg/mL of rhIL-15 before evaluating the epithelial (cytokeratins) and
mesenchymal (vimentin) markers expression by flow cytometry. RhIL-15 induced EMT was counterbalanced only in IL-2Rc/JAK3 co-transfected RCC.
Mean fluorescence intensity values for each marker are shown in each histogram. Results are representative of three experiments.
doi:10.1371/journal.pone.0031624.g007
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